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P450 3A activity and cyclosporine dosing 
in kidney and heart transplant recipients 
Interpatient differences in the kinetics of cyclosporine appear to result in part from interindividual dif- 
ferences in the catalytic activity of an enzyme termed P450 3A. We investigated the relationship between 
P450 3A activity, as measured by the erythromycin breath test (ER/vIBT), and the appropriate stable 
daily dose of cyclosporine as currently determined by physicians at our institution. The ERMBT was 
administered to kidney and heart allograft recipients who had attended at least two monthly clinic visits 
without having their daily cyclosporine dose changed. There was a significant positive correlation be- 
tween the ERMBT result and the daily cydosporine doses (in milligrams per kilogram) in both the heart 
(r = 0.68; p = 0.04; n = 9) and kidney (r = 0.68; p = 0.03; n = 10) recipients. To confirm our 
findings, we prospectively administered the ERMBT on multiple occasions to 20 patients who were un- 
dergoing kidney transplantation. Although the transplant physicians were blinded to the ERM.BT re- 
sults, the test predicted the stable daily doses of cyclosporine that they ultimately prescribed to the pa- 
tients (r = 0.54; p = 0.015). When data from all 39 patients were pooled and subjected to multiple 
regression analysis, the ERMBT was the only variable examined that significantly correlated with the 
stable daily cyclosporine dose (r = 0.63; p < 0.001; n = 39). In the 20 patients prospectively studied, 
the prescribed daily dose of cydosporine generally decreased during the months after surgery and the 
percentage changes in cyclosporine daily dose correlated with changes in P450 3A activity during this 
period (r = 0.47; p = 0.03). We conclude that interpatient and intrapatient differences in P450 3A 
activity in part account for the cydosporine dosing practices of transplant physicians. (CLIN PHARMACOL 
THER 1994;56:253-60.) 
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The daily dose of cyclosporine that suppresses or- 
gan rejection while minimizing toxicity varies at least 
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tenfold among organ transplant recipients.1 The major 
pathway for elimination of cyclosporine involves hy- 
droxylation and demethylation by a cytochrome P450, 
termed P450 3A1-4 (in this article, the term P450 3A 
is used to denote all the possible gene products of the 
CYP3A gene subfamily5), which is present in the 
liver6:7 and in intestinal mucosa." We have previ- 
ously used the [14C N-methyl]erythromycin breath test 
(ERMBT) to show that interpatient differences in 
P450 3A activity /c/.1/ account in part for interpatient 
heterogeneity in the pharmacokinetics of cyclosporine. 
The ERMBT is based on the observations that P450 
3A exclusively catalyzes the N-demethylation of 
erythromycin in the liver. The fate of the cleaved 
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methyl carbon is to promptly appear in the breath as 
carbon dioxide.12 Hence, the rate at which 14CO2 is 
exhaled after an intravenous injection of [14C N-meth- 
yl[erythromycin reflects the liver activity of P450 3A. 
We have previously reported that the ERMBT results 
correlated with mean trough blood levels of cyclospor- 
ine in 32 patients with psoriasis receiving fixed doses 
of cyclosporine for 16 weeks.13 In a second study of 
16 kidney transplant recipients, we showed that the 
ERMBT results correlated with the apparent oral 
clearance of cyclosporine at steady state.14 
Because there does not always appear to be a good 
correlation between the pharmacokinetics and pharma- 
codynamics of cyclosporine, it cannot necessarily be 
concluded from our previous studies that measure- 
ments of P450 3A activity will provide useful infor- 
mation to clinicians administering cyclosporine. Some 
patients maintained with relatively low trough blood 
levels of cyclosporine will show significant drug tox- 
icity, whereas others with relatively high cyclosporine 
blood levels will experience organ rejection. /5-17 
Thus, although the physician may use target cyclo- 
ERMBT, [14C N-methyljErythromycin breath test; qd, every day; tid, three times a day; bid, twice a day. 
*Mean of two to three trough blood levels obtained while receiving the indicated dose. 
tPatient A. 
sporine trough level ranges as a general guide to med- 
ication administration, the ultimate maintenance dose 
for a given patient is frequently determined after many 
small dosage adjustments based largely on clinical 
suspicion of organ rejection or drug toxicity.' Cyclo- 
sporine dosing is particularly difficult in kidney trans- 
plant recipients because organ dysfunction from neph- 
rotoxicity can be difficult to distinguish from 
rejection. 
In this study, we investigated the relationship be- 
tween the ERMBT result and appropriate cyclosporine 
dosing as it is currently determined for solid organ 
transplant recipients by their physicians. Our data sup- 
port the hypothesis that interpatient and intrapatient 
variation in P450 3A activity largely accounts for the 
cyclosporine dosing requirements of transplant recipi- 
ents. 
METHODS 
Patients studied. In the first phase of the study, we 
administered the ERMBT to 10 kidney and 10 heart 
transplant recipients. Patient characteristics are dis- 
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Table I. Stable organ recipients 
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Age 
Sex (yr) 
Months 
since 
transplant 
ERMBT 
(% 1401 
hr) 
Cyclosporine 
level 
(nglml)* 
Cyclosporine 
dose 
(mg/kg) Dosing 
Months 
receiving 
this 
dose 
Azathioprine 
dose (mg/kg) 
Prednisone 
dose 
(mg/kg) 
Kidney transplant 
Male 33 12 3.36 71.25 3.43 qd 2 0.86 0.11 
Male 30 11 2.96 58.8 4.71 qd 9 1.47 0.12 
Female 49 49 3.70 83.25 5.89 qd 18 0.00 0.13 
Male 57 30 1.17 165.0 1.97 qd 5 0.87 0.12 
Male 40 11 2.79 52.25 3.75 qd 9 1.56 0.13 
Male 32 21 1.43 74.5 4.72 qd 6 1.97 0.16 
Male 59 26 3.42 67.5 4.76 qd 19 0.95 0.05 
Male 30 39 4.72 86.3 4.54 qd 1.5 1.77 0.14 
Male 52 9 1.32 107.25 2.82 qd 4 0.56 0.11 
Female 54 33 1.22 100.3 1.90 qd 12 0.00 0.09 
Mean 43.6 24.1 2.61 86.64 3.85 9 1.00 0.12 
Heart transplant 
Malet 55 36 8.24 209.3 15.25 tid 26 1.63 0.20 
Female 60 18 2.04 242.7 4.05 bid 7 1.73 0.23 
Male 52 19 0.88 108.3 1.23 bid 5 1.76 0.18 
Male 32 22 2.21 100.2 2.97 bid 6 1.98 0.20 
Male 42 13 1.1 267.0 3.34 bid 5 1.48 0.15 
Male 54 35 3.27 189.7 3.48 bid 8 0.70 0.07 
Male 44 52 2.06 271.8 3.22 bid 7 0.24 0.12 
Female 54 7 1.22 322.3 4.10 bid 3 1.51 0.18 
Female 51 25 4.68 88.2 6.00 bid 8 2.00 0.15 
Male 49 9 3.07 191.0 7.13 bid 2.5 1.53 0.13 
Mean 49.3 23.6 2.88 199.07 5.087 8 1.46 0.16 
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played in Table I. Women with reproductive potential 
and children under 18 years of age were excluded. 
Each subject had to have been prescribed the identical 
daily dose of cyclosporine for at least 6 weeks (mean, 
8 weeks) and must have attended at least two consec- 
utive monthly clinic visits without changes in their cy- 
closporine dosing. All patients were considered by 
their primary physician to be medically stable and to 
be without evidence of organ rejection or significant 
cyclosporine toxicity. 
Dosing of cyclosporine was determined for each pa- 
tient by his or her own physician (five kidney trans- 
plant physicians and a single heart transplant physi- 
cian). Kidney recipients received cyclosporine as a 
single daily dose, whereas nine of the 10 heart trans- 
plant recipients received cyclosporine in two equal 
daily doses. The remaining heart recipient received 
three daily doses of cyclosporine. All patients were 
tested at least 6 months after transplant surgery (mean, 
221/2 months). The patients took their usual cyclospor- 
ine morning doses immediately after the breath test. 
In the prospective phase of the study, patients were 
enrolled before undergoing kidney transplant surgery. 
Women with reproductive potential and children under 
18 years of age were excluded. Patients received the 
ERMBT on four occasions: before surgery (ERMBT 
1), in the immediate postoperative period just before 
cyclosporine therapy was started (ERMBT 2), at an 
early outpatient clinic visit 1 to 4 months (mean, 21/2 
months) after transplantation (ERMBT 3), and after 
the patient had attended two consecutive monthly 
clinic visits without a change in his or her prescribed 
daily dose of drug (ERMBT 4). At the time of the 
fourth breath test, these patients satisfied the entrance 
criteria for our initial (retrospective) study. Physicians 
adjusting the cyclosporine dosing were blinded to the 
ERMBT results throughout the study. 
A sample size of 20 was chosen to allow an 80% 
likelihood of rejecting the null hypothesis (no correla- 
tion between the ERMBT results and the stable cyclo- 
sporine dose) if the true correlation between the pa- 
rameters was 0.6. Therefore the data was analyzed 
after the first 20 consecutively enrolled patients com- 
pleted the final breath test (ERMBT 4). Five addi- 
tional patients were enrolled but never completed the 
study. Four of these patients died of causes unrelated 
to cyclosporine (or the ERMBT) and one patient re- 
jected his transplanted kidney. 
It was our intent to enroll every eligible patient un- 
dergoing kidney transplantation surgery. Twenty-three 
women with reproductive potential, four children, two 
patients with possible erythromycin allergy, and two 
patients undergoing combined kidney and pancreas 
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transplantation were excluded. One patient refused to 
participate in the study. 
Investigational administration of the ERMBT to 
these patients was approved by the Institutional Re- 
view Board of the University of Michigan Medical 
Center. Participants provided separate written consent 
for the ERMBT portion of the study. 
[14C N-methylgrythromycin breath test. The 
erythromycin breath test was administered as de- 
scribed previously,12 except that a single breath col- 
lection was made. Three microcuries of [14C N-meth- 
yllerythromycin (0.074 !Imo') (DuPont NEN Research 
Products, Boston, Mass.) were dissolved in 2.5 ml of 
5% dextrose in water immediately before intravenous 
administration. Twenty minutes after the injection, pa- 
tients were instructed to exhale through a tube, creat- 
ing bubbles in 4 ml of hyamine hydroxide and ethanol 
(1:1) to which a trace amount of thymolphthalein had 
been added. When 2 mmol carbon dioxide had been 
trapped, which took approximately 40 seconds of ex- 
halation, the blue color vanished. The vials were then 
capped and transported to the laboratory. Twelve mil- 
liliters of Aquasol (DuPont NEN Research Products) 
were added to each vial and the specific activity of 
carbon 14 determined by scintillation counting. The 
percentage of administered carbon 14 exhaled per 
minute was calculated assuming an endogenous car- 
bon dioxide production equal to 5 mmol CO2/m2 body 
surface area/min.18 We have found that the rate of 
carbon 14 exhalation calculated from a single breath 
collection obtained at 20 minutes correlated well with 
the percentage of administered label exhaled in 1 hour 
calculated from breath samples obtained every 10 
minutes (r = 0.95; Watkins PB, unpublished results, 
May 1990). Breath test results are expressed as the 
percentage of administered carbon 14 exhaled during 
the first hour after injection of the erythromycin/2 as 
estimated by the following equation: 
(% '4C administered exhaled/min at 20 minutes 
x 43.917) + 0.38338 
We have shown that the results of the ERMBT remain 
valid when patients are receiving treatment with cy- 
closporine.13 
Measurement of cyclosporine blood levels. Parent 
cyclosporine was measured in whole blood according 
to an established HPLC technique.19 
Statistical analysis. Multiple regressions were per- 
formed with SAS (Statistical Analysis System) GLM 
procedure (SAS Institute Inc., Cary, N.C.). Hemato- 
crit and serum lipid fractions were not uniformly ob- 
tained in patients and were therefore not considered to 
be independent variables in the regressions. However, 
16 - 
12 
8 
4 
0 
we have not detected significant correlations between 
these variables and cyclosporine phannacokinetics in 
two previous studies.'3"4 One heart transplant patient 
(patient A in Table I) received 15.25 mg/kg/day cy- 
closporine and had a breath test result of 8.24 (per- 
centage of administered carbon 14 exhaled in breath in 
1 hour); each of these values is almost twice that of 
any other patient. Patient A had a seizure disorder 
and was receiving phenytoin, a known P450 3A in- 
ducer.20 All analyses were performed with and with- 
out data from this patient. When the results differed, 
the results of both analyses are given. 
RESULTS 
Correlation between the ERMBT result and stable 
cyclosporine dose. The ERMBT was administered to 
10 kidney and 10 heart transplant recipients who were 
receiving cyclosporine therapy (see Table I for patient 
characteristics). Each patient had attended at least two 
consecutive monthly clinic sessions since the last 
change in his or her daily cyclosporine dose. We 
therefore assumed that each patient was receiving an 
"appropriate" dose of cyclosporine in the opinion of 
his or her physician. The stable daily dose of cyclo- 
sporine (in milligrams per kilogram) received by the 
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0 2 4 6 8 10 
ERMBT (%C-14 exhaled/hr) 
Fig. 1. The correlation between the erythromycin breath test (ERMBT) result and the daily dose 
of cyclosporine (CsA) prescribed to 10 stable heart (triangles) and kidney (circles) transplant re- 
cipients. There was a significant correlation between the ERMBT result and the daily dose of cy- 
closporine prescribed to each patient when all patients were considered (r 0.75; p < 0.001; n = 
20). The correlation remained significant when the patient receiving 15 mg/kg/day (asterisk, pa- 
tient A in Table I) was excluded (r = 0.67; p = 0.002; n = 19). When analyzed separately, 
significant correlations were also observed in the kidney recipients (r = 0.68; p = 0.03; n = 10) 
and in the heart recipients (r = 0.68; p = 0.04; n = 9; excluding patient A). 
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patients varied approximately sixfold (Table I). Whole 
blood parent cyclosporine levels varied approximately 
threefold in each transplant group (Table I). This is 
consistent with the concept that physicians' decisions 
regarding administration of cyclosporine are not 
guided solely by blood level monitoring. Among these 
20 patients, the correlation between the ERMBT re- 
sults and the ratios of observed cyclosporine blood 
level to daily cyclosporine dose (in milligrams per ki- 
logram per day) was 0.63 (p = 0.003; data not 
shown). 
As shown in Fig. 1, there was a positive correlation 
between the ERMBT result and the cyclosporine dose 
(r = 0.75; p < 0.001; n = 20). When the single pa- 
* 
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tient with both the highest ERMBT result and largest 
daily cyclosporine dose (patient A, Fig. 1) was ex- 
cluded, the correlation remained significant (r = 0.67; 
p = 0.002; n = 19). 
To determine if other patient characteristics or labo- 
ratory parameters might also predict dosing of cyclo- 
sporine, a stepwise regression was performed. The 
predictor variables ERMBT result, cyclosporine blood 
concentration, transplant type (kidney or heart), 
months after transplant, gender, age, weight (in kilo- 
grams), azathioprine dose (in milligrams per kilo- 
gram), prednisone dose (in milligrams per kilogram), 
and traditional liver chemistries (alanine aminotrans- 
ferase, aspartate aminotransferase, alkaline phos- 
0 2 4 6 8 10 
ERMBT (%C-14 exhaled/hr) 
Fig. 2. The correlation between the ERMBT result and the stable dose of cyclosporine prescribed 
to the 20 prospectively followed kidney transplant recipients (squares) and to the 10 heart and 10 
kidney recipients initially studied (diamonds, patient A shown by asterisk). Among the prospec- 
tively followed patients, there was a significant correlation between the ERMBT result (ERMBT 
4) and the stable cyclosporine dose the patients were taking at the time of the test (r = 0.54; p = 
0.015; n = 20). The 90% prediction limits (broken lines) are shown for all 39 patients (excluding 
patient A [asterisk]). 
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phatase, and bilirubin) were entered into a regression 
equation with the dependent variable cyclosporine 
dose (in milligrams per kilogram per day). Predictor 
variables were then deleted until only those significant 
at a p < 0.05 level remained ("backward" selection). 
When all 20 patients were included, the resulting 
model (not shown) included only the ERMBT (p < 
0.001) and prednisone dose (p = 0.03). When patient 
A was deleted, the final model contained only the 
ERMBT (p <0.01). 
Within the heart transplant group, the coefficient of 
correlation (r) between the ERMBT and the cyclospor- 
ine dose was 0.92 (p <0.001) when patient A was in- 
cluded and 0.68 (p = 0.04; n = 9) when patient A was 
excluded (Fig. 1). In the kidney recipients, the correla- 
tion coefficient was also 0.68 (p = 0.03; n = 10). 
Prospective study of kidney transplant recipients. 
We next prospectively administered the ERMBT on 
four occasions to patients undergoing kidney trans- 
plantation. The ERMBT results rose in most patients 
between the first and second breath test (correspond- 
ing to immediately before surgery and after surgery 
just before cyclosporine was started, respectively); 
however, this increase did not reach significance (not 
shown). There was also no significant difference be- 
tween the mean ERMBT result at the time of the sec- 
ond and third tests (not shown): However, there was a 
significant decrease in the mean ERMBT result be- 
tween the third ERMBT (mean, 4.2%; SD, 1.8%), 
performed at an early outpatient clinic visit, and the 
fourth ERMBT (mean, 3.2%; SD, 1.2%), performed a 
mean of 8.6 months after surgery (p = 0.002, paired 
t test). 
At an early outpatient clinic visit (the third 
ERMBT, a mean of 21/2 months after surgery), there 
was a significant correlation between the patients' 
ERMBT values and the doses of cyclosporine pre- 
scribed (r = 0.55; p = 0.01). There was also a signif- 
icant correlation between the final stable dose of cy- 
closporine prescribed and ERMBT results obtained at 
the time of the fourth ERMBT, a mean of 8.6 months 
after surgery (r = 0.54; p = 0.015; Fig. 2). At this 
time, the correlation between the ERMBT results and 
the ratios of cyclosporine blood level to daily dose 
was 0.60 (p = 0.005). 
There was a significant correlation between the per- 
centage of change in cyclosporine dose and the per- 
centage of change in ERMBT result between the time 
of the third and fourth ERMBT (r = 0.472; p = 
0.037). Hence, patients who had decreases in ERMBT 
results generally had a reduction in their prescribed 
doses of cyclosporine. 
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Table II. Correlations between cyclosporine dose (in 
milligrams per kilogram per day) and various patient 
characteristics or laboratory parameters in the 39 
patients shown in Fig. 2* 
AST, Aspartate aminotransferase; ALT, alanine aminotransferase. 
*Patient A not included. 
At the time of the fourth breath test, the prospec- 
tively recruited kidney transplant recipients satisfied 
the entrance criteria used in the original retrospective 
study (i.e., attending two consecutive clinic visits 
without a change in the daily cyclosporine dose). We 
therefore pooled the prospective data with those ob- 
tained from the kidney and heart transplant patients 
originally studied (Fig. 1). As shown in Table II, the 
ERMBT was the only variable examined that signifi- 
cantly correlated with daily cyclosporine dose. A mul- 
tiple regression was then performed with the stable cy- 
closporine dose as the dependent variable and 
ERMBT result, gender, age,. weight (in kilograms), 
azathioprine dose (in milligrams per kilogram), pred- 
nisone dose (in milligrams per kilogram), and tradi- 
tional liver chemistries (alanine aminotransferase, 
aspartate aminotransferase, alkaline phosphatase, and 
total bilirubin) as independent variables. After step- 
wise deletion of variables (see Methods section), the 
resulting model included only the ERMBT (p < 
0.0001). When patient A (Table I) was deleted, the fi- 
nal model also contained only the ERMBT (r = 0.63; 
p < 0.001). Thus interpatient differences in the 
ERMBT results accounted for 40% of the variability 
in prescribed cyclosporine dosing in the 39 patients 
(r2 = 0.40). The correlation between the ERMBT re- 
sults and the cyclosporine blood level/dose ratios was 
essentially identical (r -= 0.63; r2 = 0.40). 
DISCUSSION 
Interindividual differences in P450 3A activity ac- 
count in part for interpatient differences in the phar- 
macokinetics of cyclosporine. /3'14 The ERMBT pro- 
vides a convenient means of measuring P450 3A 
Variable 
ERMBT (% '4C exhaled/hr) 0.63 0.0001 
Gender 0.089 0.59 
Age (yr) 0.12 0.62 
Weight (kg) 0.30 0.061 
Azathioprine dose (mg/kg) 0.22 0.90 
Prednisone dose (mg/kg) 0.080 0.63 
AST (IU/L) 0.16 0.33 
ALT (IU/L) 0.011 0.95 
Alkaline phosphatase (IU/L) 0.051 0.76 
Total bilirubin (mg/di) 0.007 0.96 
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activity12 and we have shown that the ERMBT pre- 
dicts the pharmacokinetics of cyclosporine at steady 
state. The significant correlations we found between 
the ERMBT results and the cyclosporine blood level/ 
daily dose ratios in the current studies further confirm 
our previous observations. However, the relationship 
between an individual's P450 3A catalytic activity and 
the actual dose of cyclosporine administered in clini- 
cal practice had not been investigated previously. 
In the first phase of this study, we demonstrated 
that the ERMBT result correlated with the stable doses 
prescribed to 20 kidney and heart transplant recipients 
who were apparently at steady state for cyclosporine 
(Fig. 1). This correlation was then confirmed in a pro- 
spective analysis of patients undergoing kidney trans- 
plantation. We found that the patients' P450 3A activ- 
ities, as measured by the ERMBT, correlated with the 
daily cyclosporine doses prescribed by physicians both 
at an early outpatient clinic visit and when patients 
achieved stable cyclosporine dosing at a mean of 8.6 
months after surgery (Fig. 2). When the data from the 
initial and prospective studies were pooled, the 
ERMBT result was the only variable that significantly 
predicted the stable dose of the drug (Table II). Even 
when the data from patient A was excluded, the 
ERMBT result accounted for 40% of the variability in 
cyclosporine dosing observed in this population (r2 = 
0.40). Other patient characteristics or laboratory pa- 
rameters (including traditional liver chemistries) ap- 
peared to have no correlation with the cyclosporine 
dose in these multiple regression analyses. We con- 
clude that interpatient differences in P450 3A activity 
may largely account for the heterogeneity in cyclo- 
sporine dosing requirements. 
A reduction in the cyclosporine dosing requirement 
is generally observed in kidney transplant recipients 
during the first year after surgery, although there is no 
accepted explanation for this phenomenon.20'21 There 
was also a reduction in the mean daily dose of cyclo- 
sporine prescribed to our patients during the study (not 
shown). This was associated with a decrease in the 
mean ERMBT result and there was a correlation be- 
tween the percentage of change in the ERMBT result 
and the percentage of change in the daily prescribed 
dose of cyclosporine between the third and fourth 
tests. It therefore seems likely that the reduction in re- 
quired dose of cyclosporine that occurs during the first 
year after transplant surgery in part results from a ten- 
dency for P450 3A activity to decrease during this pe- 
riod. 
The reasons for the decrease in P450 3A activity in 
the months after transplant surgery are unclear. In this 
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regard, it may be important that all of the patients re- 
ceived prednisone, a known inducer of P450 3A in 
cultured human hepatocytes.22 The mean daily dose of 
prednisone received by patients was reduced by ap- 
proximately 50% between the third and fourth breath 
tests (data not shown). A plausible hypothesis is that 
withdrawal of this inducer partially accounted for the 
reduction in P450 3A activity. 
In a previous study involving patients treated with 
cyclosporine for psoriasis, we derived a mathematical 
model that could account for the majority of variation 
in observed cyclosporine blood levels using the vari- 
ables of cyclosporine daily dose, ERMBT result, and 
patient age.13 When this model was applied to the 
data in this study, a statistically significant correlation 
between the observed blood levels and those predicted 
from the model was found in each subset of patients 
(data not shown). However, the actual predictive ca- 
pacity of the model was far lower in the transplant re- 
cipients than in the patients with psoriasis. For exam- 
ple, the correlation was only 0.5 when all 40 patients 
were examined (p = 0.001), whereas a correlation of 
0.83 was obtained in the 32 patients with psoriasis.13 
The poorer correlation in the transplant recipients 
probably reflects the numerous differences between 
our psoriasis study and the current study. For exam- 
ple, the dosing regimens differed among our trans- 
plant recipients (Table I). In addition, the transplant 
recipients were receiving multiple medications and 
had concomitant diseases that would be likely to influ- 
ence the predictive model. 
An important question not addressed by our studies 
is whether the ERMBT would be useful in prescribing 
cyclosporine. Based on our data (Fig. 2), it seems 
likely that the test could potentially identify some in- 
dividuals who may require unusually high or unusu- 
ally low doses of the drug. Because of the long blood 
half-life of cyclosporine, it can take many days or 
weeks to arrive at the appropriate steady-state dose of 
cyclosporine for these individuals when guided solely 
by blood levels. The ERMBT may also be useful in 
evaluating patients with unexpected changes in their 
apparent dosing requirements. The discovery that such 
a patient's prescribed daily cyclosporine dose and 
ERMBT result lie outside the 90% prediction limits 
(Fig. 2) could support suspicions of noncompliance. 
Alternatively, if the patient's values lie within the pre- 
diction limits, concomitant treatment with P450 3A 
inducers or inhibitorsm'l 1 would be suggested. 
In summary, our data supports the hypothesis that 
interpatient and intrapatient differences in P450 3A 
activity largely account for the heterogeneity in 
260 Turgeon et al. 
physician-derived dosing regimens for cyclosporine. 
Prospective clinical trials should now be undertaken to 
evaluate the usefulness of the ERMBT as a guide to 
monitoring therapy with cyclosporine. 
We thank Anne McKay, Diane Tramel, and Jane 
Waskerwitz for their assistance in recruiting patients for this 
study. 
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